Indonesia Neurology Clinical Trials Market Report 2022 to 2030

Indonesia Neurology Clinical Trials Market Analysis

$ 3999

The Indonesia Neurology Clinical Trials market is projected to grow from $31.4 Mn in 2022 to $48.2 Mn by 2030, registering a CAGR of 5.5% during the forecast period of 2022 - 2030. The market will be driven by the rising investments by global pharmaceutical companies in Indonesia due to reduced operating costs and improved healthcare infrastructure. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis, Roche & PT Dexa Medica.

ID: IN10IDCT005 CATEGORY: Clinical Trials GEOGRAPHY: Indonesia AUTHOR: Vidhi Upadhyay

Buy Now

Indonesia Neurology Clinical Trials Market Executive Summary

The Indonesia Neurology Clinical Trials market is projected to grow from $31.4 Mn in 2022 to $48.2 Mn by 2030, registering a CAGR of 5.5% during the forecast period of 2022 - 2030. Healthcare is a national priority in Indonesia, and the central and provincial governments are continuing to create and improve healthcare facilities. Indonesia now has 2,925 hospitals, with approximately 63% privately operated. According to the Indonesian Statistic Bureau, there were 10,205 public Health Community Centers (PUSKESMAS) in operation by 2020, providing complete basic healthcare and immunisations.

Clinical trials are critical for the development of novel therapies and the development of evidence-based medicine, which is regarded as the finest medical care. Participation in clinical trials enables to provide patients with cutting-edge therapy while also allowing them to contribute to the development of care for future patients. There are several ongoing neurology clinical trial activities in Indonesia, including trials for treatments of Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy mostly in Phase ll, Phase lll and Phase lV stages. Several hospitals such as Cipto Mangunkusumo Hospital, Jakarta; Dr. Soetomo General Hospital, Surabaya; Siloam Hospitals Group; National Brain Center Hospital, Jakarta & Adventist Hospital, Bandung are involved in such trials.

These trials are often undertaken in partnership with local hospitals and clinics by both local and multinational pharmaceutical corporations. Clinical trial operations in Indonesia are projected to expand in the future years as more corporations and researchers realise the country's potential as a clinical research destination.

Indonesia Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

As more hospitals and clinics are developed around the nation, Indonesia's healthcare infrastructure is improving. This has raised the potential for attracting research participants, Numerous global pharmaceutical companies are exhibiting interest in Indonesia as a location for clinical trials, notably in the area of neurology. This is due in part to the country's increasing frequency of neurological illnesses and the enormous prospective patient population. Reduced operating expenses in comparison to Western markets, A large number of treatment-naive patients and a diverse demographic. A better regulatory environment is some other contributors to the growth of the market.

Market Restraints

Indonesia has inadequate financing and resources for clinical trials, which might be a barrier to doing research. There is a paucity of experienced investigators and staff, especially in the area of neurology, making clinical trials difficult to run. Language limitations may make conducting clinical trials in Indonesia difficult, especially for international sponsors who may not have access to multilingual personnel or translators. All of these factors might impede the growth of the neurology clinical trials market in Indonesia.

Competitive Landscape

Key Players

Pfizer
Novartis
Roche
Sanofi
Merck & Co.
GlaxoSmithKline
Johnson & Johnson
AstraZeneca
PT Kalbe Farma Tbk (IDN)
PT Dexa Medica (IDN)
PT Kimia Farma (IDN)

Healthcare Policies and Regulatory Landscape

Clinical trials are governed in Indonesia by the Indonesian Ministry of Health, also known as the Badan Pengawas Obat dan Makanan (BPOM). To be approved by the BPOM, all clinical studies must adhere to this regulation.

Clinical trials in Indonesia may be carried out directly by the sponsor or via a contract research organisation (CRO), as long as the CRO is headquartered in Indonesia and follows Good Clinical Trial Practice guidelines.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.